Sunesis Pharmaceuticals Announces Presentation at 61st American Society of Hematology Annual Meeting
November 06 2019 - 9:16AM
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a
poster presentation at the 61st American Society of Hematology
(ASH) Annual Meeting to be held December 7-10, 2019 in Orlando,
Florida.
The details for the poster presentation are as
follows:
Date and Time: Sunday, December
8, 2019, 6:00-8:00 pm ET Abstract Title: Ongoing
Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study
of the Selective, Noncovalent, Reversible Burton’s Tyrosine Kinase
Inhibitor, Vecabrutinib, in B-Cell Malignancies
Session Name: CLL:
Therapy, excluding Transplantation: Poster IIPublication
Number: 3041Location: Orange County
Convention Center, Hall B
The abstract can be viewed here. The poster
presentation will include more recent data.
About Sunesis
Pharmaceuticals
Sunesis is a biopharmaceutical company
developing novel targeted inhibitors for the treatment of
hematologic and solid cancers. Sunesis has built an experienced
drug development organization committed to improving the lives of
people with cancer. The Company is focused on advancing its novel
kinase inhibitor pipeline, with an emphasis on its oral
non-covalent BTK inhibitor vecabrutinib. Vecabrutinib is currently
being evaluated in a Phase 1b/2 study in adults with chronic
lymphocytic leukemia and other B-cell malignancies that have
progressed after prior therapies.
For additional information on Sunesis, please
visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis
Pharmaceuticals, Inc.
This press release contains forward-looking
statements, including statements related to the continued
development of vecabrutinib (SNS-062). Words such as "may,"
“intend,” “will,” “potential,” “look forward,” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Sunesis' current
expectations. Forward-looking statements involve risks and
uncertainties. Sunesis' actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties. These and other risk factors are discussed under
"Risk Factors" in Sunesis' Quarterly Report on Form 10-Q for the
quarter ended June 30, 2019 and Sunesis' other filings
with the Securities and Exchange Commission. Sunesis expressly
disclaims any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained
herein to reflect any change in Sunesis' expectations with regard
thereto or any change in events, conditions or circumstances on
which any such statements are based.
Investor and Media Inquiries:Maeve ConneightonArgot
Partners212-600-1902 |
Willie QuinnSunesis Pharmaceuticals Inc.650-266-3716 |
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2023 to Sep 2024